Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Patent
1993-08-20
1996-12-17
Smith, Lynette F.
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
4351723, 4353201, 4241881, 4242071, 4242081, 514 2, 530350, 530395, A61K 3921, C12P 2106, C12N 1500, C07K 100
Patent
active
055852505
ABSTRACT:
The present invention provides a composition that can be administered to a mammal to cause immunoprotection in the mammal against a pathogenic organism that has an immunodominant epitope. The composition includes a modified form of the antigen in which the immunodominant epitope is located. In this modified form, the immunodominant epitope is immunodampened by any of a number of techniques. Examples of immunodampening techniques include addition of N-linked glycosylation sites, change of the net charge on the epitope, and substitution with a tolerated sequence. The composition also includes a pharmacologically acceptable carrier.
REFERENCES:
Haynes, B.F. Science 260;1279-1286, 1993.
Kumar, V. et al. Proc. Natl. Acad. Sci. USA 87:1337-1341, 1990.
Haigwood, N.L. et al. Aids Res. Hum. Rertro. 6(7):855-869, 1990.
Girard, M. et al. Proc. Natl. Acad. Sci. USA. 88:542-46, 1991.
Berman, P. et al. Nature 345:622-625, 1990.
Neurath, A. R. et al. Molec. Immunol. 27(6):539-549, 1990.
S. Olofsson, et al.; Vaccines 93.; pp. 183-187; "Peripheral Carbohydrate structures engaged in regulation of antigenic properties of HIV-1 gp120".
A. Bolmstedt, et al.; Journal of General Virology; vol. 73, No. 12, Dec. 1992, pp. 3099-3105; "Carbohydrate determinant NeuAc-Galbeta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120".
P. Simmonds, et al.; Journal of Virology; vol. 164, No. 12, Dec. 1990; pp. 5840-580; "Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1".
H. Kohler, et al.; Journal of Acquired Immune Deficiency Syndromes; vol. 5, No. 11, Nov. 1992; "Clonal Dominance: Cause for a limited and failing immune response to HIV-1 infection and vaccination".
R. Garrity, et al.; Aids Research and Human Retroviruses; vol. 10, No. SUP1; Aug. 1993; "Introduction of potential N-linked glycosylation sites into the V3 domain of HIV-1 gp120: Effects on virus viability, antigenicity and immunogenicity".
Garrity Robert R.
Goudsmit Jaap
Nara Peter L.
Smith Lynette F.
The United States of America as represented by the Department of
LandOfFree
Dampening of an immunodominant epitope of an antigen for use in does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dampening of an immunodominant epitope of an antigen for use in , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dampening of an immunodominant epitope of an antigen for use in will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1990472